Excessive Weight Gain Associated With Dolutegravir Initiation in a 10-Year-Old Female With Perinatally Acquired Human Immunodeficiency Virus: A Case Report and Review of the Literature
- PMID: 32448908
- DOI: 10.1093/jpids/piaa052
Excessive Weight Gain Associated With Dolutegravir Initiation in a 10-Year-Old Female With Perinatally Acquired Human Immunodeficiency Virus: A Case Report and Review of the Literature
Abstract
Children with perinatally acquired human immunodeficiency virus (PHIV) face a lifetime of combination antiretroviral treatment that often includes dolutegravir (DTG). DTG, an integrase strand inhibitor that has been linked to weight gain in adults, is increasingly being used in children. Understanding its potential short- and long-term sequelae in children is critically important. We report a case of excessive weight gain in a child with PHIV on DTG and provide a brief literature review.
Keywords: dolutegravir; human immunodeficiency virus (HIV); pediatric; perinatal; weight gain.
© The Author(s) 2020. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Prevalence of overweight and obesity among adolescents living with HIV after dolutegravir - based antiretroviral therapy start in Kampala, Uganda.AIDS Res Ther. 2024 Apr 18;21(1):23. doi: 10.1186/s12981-024-00615-6. AIDS Res Ther. 2024. PMID: 38637785 Free PMC article.
-
Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy.Clin Infect Dis. 2020 Mar 17;70(7):1267-1274. doi: 10.1093/cid/ciz407. Clin Infect Dis. 2020. PMID: 31100116 Free PMC article.
-
No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV.AIDS. 2020 Jan 1;34(1):109-114. doi: 10.1097/QAD.0000000000002379. AIDS. 2020. PMID: 31567162
-
Doing More With Less: Review of Dolutegravir-Lamivudine, a Novel Single-Tablet Regimen for Antiretroviral-Naïve Adults With HIV-1 Infection.Ann Pharmacother. 2020 Dec;54(12):1252-1259. doi: 10.1177/1060028020933772. Epub 2020 Jun 9. Ann Pharmacother. 2020. PMID: 32517480 Review.
-
Perspectives on the Barrier to Resistance for Dolutegravir + Lamivudine, a Two-Drug Antiretroviral Therapy for HIV-1 Infection.AIDS Res Hum Retroviruses. 2020 Jan;36(1):13-18. doi: 10.1089/AID.2019.0171. Epub 2019 Oct 21. AIDS Res Hum Retroviruses. 2020. PMID: 31507204 Free PMC article. Review.
Cited by
-
Integrase Strand Transfer Inhibitors and Weight Gain in Children and Youth With Perinatal Human Immunodeficiency Virus in the DC Cohort.Open Forum Infect Dis. 2021 Jul 1;8(7):ofab308. doi: 10.1093/ofid/ofab308. eCollection 2021 Jul. Open Forum Infect Dis. 2021. PMID: 34295943 Free PMC article.
-
Research priorities for accelerating the achievement of three 95 HIV goals in Cameroon: a consensus statement from the Cameroon HIV Research Forum (CAM-HERO).Pan Afr Med J. 2021 Oct 29;40:124. doi: 10.11604/pamj.2021.40.124.31068. eCollection 2021. Pan Afr Med J. 2021. PMID: 34909092 Free PMC article.
-
Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents.Clin Infect Dis. 2021 Aug 2;73(3):e580-e586. doi: 10.1093/cid/ciaa1652. Clin Infect Dis. 2021. PMID: 33119739 Free PMC article.
-
Efficacy, Safety and Tolerability of Dispersible and Immediate Release Abacavir/Dolutegravir/Lamivudine Tablets in Children With HIV: IMPAACT 2019 Week 48 Results.Pediatr Infect Dis J. 2025 May 29;44(8):777-784. doi: 10.1097/INF.0000000000004859. Pediatr Infect Dis J. 2025. PMID: 40440679 Free PMC article. Clinical Trial.
-
Growth, weight gain and BMI in virally suppressed children on antiretroviral therapy with specific reference to dolutegravir.BMC Pediatr. 2023 Jul 4;23(1):339. doi: 10.1186/s12887-023-04143-6. BMC Pediatr. 2023. PMID: 37403042 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical